Scripps 40th Annual New Treatments in Chronic Liver Disease 2026

30 $

+ Include: 13 videos +13 file sub vtt + 12 pdfs, size: 3.48 GB

+ Target Audience: hepatologists, gastroenterologists, and transplant specialists

We're processing your payment...
Please DO NOT close this page!

- OR -

Description

+ Include: 13 videos +13 file sub vtt + 12 pdfs, size: 3.48 GB

+ Target Audience: hepatologists, gastroenterologists, and transplant specialists

+ Sample video: contact me for sample video

+ Information:

1. Overview

The Scripps 40th Annual New Treatments in Chronic Liver Disease 2026 program provides a comprehensive, expert-led review of the latest therapeutic advancements and diagnostic strategies in hepatology. The course covers a broad spectrum of complex hepatic conditions, including emerging entities like MetALD, the reversibility of MASH cirrhosis, functional cures for viral hepatitis, and updates in autoimmune liver diseases, equipping clinicians to optimize patient care and transplant selection.

Course Date: 2026

New Treatments in Chronic Liver Disease will highlight the latest advancements in medications and therapies for liver care and transplantation. The program will offer an in-depth review of clinical trials and real-world data on oral treatments for chronic viral hepatitis B and C, non-alcoholic fatty liver disease, primary biliary cholangitis, primary sclerosing cholangitis, hepatocellular carcinoma, and complications of end-stage liver disease, including thrombocytopenia. This annual conference delivers a comprehensive yet targeted program designed to provide physicians with the latest updates and practical insights for managing liver diseases.

2. Learning Objectives

Upon completion of this activity, participants should be able to:
• Cite new strategies for identifying and managing metabolic liver disease.
• Review updated goals and guidelines for curing Delta Hepatitis, HBV and HCV.
• Discuss potential new treatments for alcohol-related liver disease.
• Summarize novel markers and therapies in PBC and PSC.
• Evaluate liver masses and new therapeutic options for HCC.
• Employ strategies for treating and managing ascites and hepatorenal syndrome.

3. Target Audience

Best for hepatologists, gastroenterologists, and transplant specialists who want updates on viral hepatitis, MASH, MetALD, and transplant criteria.

4. Topics

  1. 01 The Emerging Clinical Entity of MetALD Diagnosis, Risk, and Management

  2. 02 Treatment of MASH Cirrhosis Is it Reversible

  3. 03 Obesity Treatment The Essentials

  4. 04 Pediatric MASH Approaches to Diagnosis and Treatment VIDEO PDF NOT RELEASE

  5. 05 Panel Discussion Q&A

  6. 06 Updates on Diagnosis and Treatment of Autoimmune Hepatitis

  7. 07 Drug Induced Liver Injury

  8. 08 Hepatitis B Functional Cures

  9. 09 Using Medication Assisted Therapy in Hepatitis C

  10. 10 Delta Hepatitis

  11. 11 Panel Discussion Q&A

  12. 12 HCC VIDEO PDF NOT RELEASE

  13. 13 Transplant Selection Board

  14. 14 WILLIAM S. HAUBRICH LECTURE Updates in PBC and PSC

  15. 15 Panel Discussion Q&A

Reviews

There are no reviews yet.

Be the first to review “Scripps 40th Annual New Treatments in Chronic Liver Disease 2026”

Your email address will not be published. Required fields are marked *

76 − 68 =
Powered by MathCaptcha